Should patients with a pre-operative prostate-specific antigen greater than 15 ng/ml be offered radical prostatectomy?
RRP seems feasible in patients whose pre-operative PSA is between 15 and 25 ng/ml with stage T1c, Gleason score<or = 7 and negative lymph node frozen section.
These findings suggest that the CCL2/CCR2 axis is a potential therapeutic target in SSc, particularly in the early dcSSc subset. CCL2 measurement may be useful for risk stratification in early stage disease, but its value in disease monitoring is questionable.